Literature DB >> 25333850

Epigenetic modifications in prostate cancer.

Marjolaine Ngollo1, Aslihan Dagdemir, Seher Karsli-Ceppioglu, Gaelle Judes, Amaury Pajon, Frederique Penault-Llorca, Jean-Paul Boiteux, Yves-Jean Bignon, Laurent Guy, Dominique J Bernard-Gallon.   

Abstract

Prostate cancer is the most common cancer in men and the second leading cause of cancer deaths in men in France. Apart from the genetic alterations in prostate cancer, epigenetics modifications are involved in the development and progression of this disease. Epigenetic events are the main cause in gene regulation and the three most epigenetic mechanisms studied include DNA methylation, histone modifications and microRNA expression. In this review, we summarized epigenetic mechanisms in prostate cancer. Epigenetic drugs that inhibit DNA methylation, histone methylation and histone acetylation might be able to reactivate silenced gene expression in prostate cancer. However, further understanding of interactions of these enzymes and their effects on transcription regulation in prostate cancer is needed and has become a priority in biomedical research. In this study, we summed up epigenetic changes with emphasis on pharmacologic epigenetic target agents.

Entities:  

Keywords:  DNA methylation; epigenetic modifications; histone methylation; microRNA; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 25333850     DOI: 10.2217/epi.14.34

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  17 in total

Review 1.  DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate.

Authors:  Kimberly P Keil; Chad M Vezina
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

Review 2.  Emerging players in prostate cancer: long non-coding RNAs.

Authors:  Tong Sun; Huihui Ye; Chin-Lee Wu; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  Am J Clin Exp Urol       Date:  2014-12-25

3.  Exercise training as a modulator of epigenetic events in prostate tumors.

Authors:  Suzanne Dufresne; Jordan Guéritat; Carmen P Wong; Amin Isanejad; Emily Ho; Eva Serna; Marie-Carmen Gomez-Cabrera; Amélie Rebillard
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-18       Impact factor: 5.554

4.  DNA Methylome Profiling on the Infinium HumanMethylation450 Array from Limiting Quantities of Genomic DNA from a Single, Small Archived Bloodspot.

Authors:  Kripa Asrani; Gary M Shaw; Jasper Rine; Nicholas J Marini
Journal:  Genet Test Mol Biomarkers       Date:  2017-06-13

Review 5.  Exploiting Epigenetic Alterations in Prostate Cancer.

Authors:  Simon J Baumgart; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2017-05-09       Impact factor: 5.923

Review 6.  Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.

Authors:  Meng Ye; Tao Huang; Ying Ying; Jinyun Li; Ping Yang; Chao Ni; Chongchang Zhou; Si Chen
Journal:  Oncotarget       Date:  2017-02-07

7.  A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2.

Authors:  Marine Daures; Mouhamed Idrissou; Gaëlle Judes; Khaldoun Rifaï; Frédérique Penault-Llorca; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  Oncotarget       Date:  2018-05-04

8.  Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer.

Authors:  Chunyan Shen; Qifang Sheng; Xiaojie Zhang; Yuling Fu; Kemiao Zhu
Journal:  J Ovarian Res       Date:  2016-09-26       Impact factor: 4.234

9.  Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.

Authors:  Jingwen Zhao; Yu Zhao; Liguo Wang; Jun Zhang; R Jeffrey Karnes; Manish Kohli; Guixia Wang; Haojie Huang
Journal:  Oncotarget       Date:  2016-06-21

Review 10.  Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis.

Authors:  Yu Zheng; Xia Li; Yiming Jiang; Yufen Xu; Binbin Song; Qiang Zhou; Xiaodong Liang; Xinmei Yang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.